Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRIVE III
NCT07240922Phase 4Active, not recruiting
- Sponsor
- The University of Hong Kong
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal) and influenza vaccine in influenza (4 arms), sponsored by The University of Hong Kong. Primary endpoints: Target rise in Hemagglutination Inhibition (HAI) titer at 30 days, Geometric Mean Titer (GMT) ratio at 182 days and 3 more. Started Oct 2025; status: active, not recruiting.
02
Drugs
influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal)influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07240922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240922.